BioCardia, Inc. Short Interest Down 19.5 percent in December
BCDA Stock | USD 2.18 0.06 2.83% |
About 66 percent of all Biocardia's investors are curious in acquiring. The analysis of the overall investor sentiment regarding Biocardia suggests that a large number of traders are confidant. The current market sentiment, together with Biocardia's historical and current headlines, can help investors time the market. In addition, many technical investors use Biocardia stock news signals to limit their universe of possible portfolio assets.
Biocardia |
BioCardia, Inc. was the target of a significant decline in short interest in December. As of December 15th, there was short interest totalling 83,400 shares, a decline of 19.5 percent from the November 30th total of 103,600 shares. Based on an average daily volume of 55,000 shares, the short-interest ratio is
Read at thelincolnianonline.com
Biocardia Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Biocardia can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Biocardia Fundamental Analysis
We analyze Biocardia's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biocardia using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biocardia based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
Biocardia is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Biocardia Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biocardia stock to make a market-neutral strategy. Peer analysis of Biocardia could also be used in its relative valuation, which is a method of valuing Biocardia by comparing valuation metrics with similar companies.
Peers
Biocardia Related Equities
AVTE | Aerovate Therapeutics | 6.17 | ||||
ACRV | Acrivon Therapeutics, | 4.14 | ||||
RZLT | Rezolute | 2.31 | ||||
ANTX | AN2 Therapeutics | 1.60 | ||||
KTTA | Pasithea Therapeutics | 1.22 | ||||
ERAS | Erasca | 0.54 | ||||
ADAG | Adagene | 0.54 | ||||
FBRX | Forte Biosciences | 1.27 | ||||
ABVC | ABVC Biopharma | 1.82 | ||||
ANEB | Anebulo Pharmaceuticals | 1.85 | ||||
PTIX | Protagenic Therapeutics | 2.22 | ||||
NGENF | NervGen Pharma | 2.43 | ||||
MLYS | Mineralys Therapeutics, | 2.74 | ||||
INDP | Indaptus Therapeutics | 3.45 |
Complementary Tools for Biocardia Stock analysis
When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
Global Correlations Find global opportunities by holding instruments from different markets | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |